# Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

> **NCT04444284** · PHASE1 · COMPLETED · sponsor: **Meissa Vaccines, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Investigational RSV vaccine MV-012-968 (Dosage 1)
- **BIOLOGICAL:** Investigational RSV vaccine MV-012-968 (Dosage 2)
- **OTHER:** Placebo
- **BIOLOGICAL:** Investigational RSV vaccine MV-012-968 (Dosage 3)

## Key facts

- **NCT ID:** NCT04444284
- **Lead sponsor:** Meissa Vaccines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-09
- **Primary completion:** 2021-05-07
- **Final completion:** 2021-05-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444284, "Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04444284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*